Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully-qualified, fraud-free breast implant cancer cases. Here at Leading Justice, we can custom-tailor your firm’s BIA-ALCL advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of breast implant lymphoma advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that isn’t eligible for the target campaign is reviewed to determine whether it qualifies for another type of claim. By using advanced approaches to target contacts specifically related to breast implants and side effects like anaplastic large cell lymphoma, Leading Justice will increase your firm’s BIA-ALCL caseload. If you are interested in helping victims of alleged breast implant-associated cancer side effects, our direct advertising strategies and extensive consumer reach at Leading Justice give you the competitive edge and confidence you need to allocate your full budget, knowing that your money is being used in the best way possible.
Each law firm we work with at Leading Justice plays an important role in determining how we classify claims as qualified or not. While our experience working with plaintiff law firms helps us recognize a great case when we see one, we will customize our breast implant-associated anaplastic large cell lymphoma case intake specifications to the exact criteria you are seeking. So, if your firm has specific breast implant cancer qualifying case criteria you would like us to use, we can train our intake specialists to apply the criteria to each email and phone call they receive. By eliminating the middle man, Leading Justice offers clients an opportunity for internal cash buys of BIA-ALCL data with zero chance of fraud.
Breast Implant-Associated ALCL Litigation
The first hint of a possible connection between breast implants and non-Hodgkin lymphoma came in 2011, when the FDA reported that “women with breast implants may have a very small but increased risk” of developing anaplastic large cell lymphoma “in the scar capsule adjacent to the implant.” At the time, there were so few cases of the disease reported, the agency was unable to determine the exact risk factors of the disease, but in the years since its initial warning, the FDA has gathered additional information about the potential risk of ALCL associated with breast implants, and now agrees with the World Health Organization’s 2016 designation of BIA-ALCL as a “rare T-cell lymphoma that can develop following breast implants.” According to reports, BIA-ALCL can occur with both saline and silicone implants, and appears to be more common in women with textured-surface implants, compared to smooth-surface implants, though both types of implants pose some risk.
As of February 2017, the FDA has received 359 reports of breast implant-associated anaplastic large cell lymphoma, a rare but deadly type of cancer that can develop within the fibrous “capsule” that develops around the implant, and at least nine deaths have been linked to the disease. Unfortunately, in most cases of BIA-ALCL, signs of the cancer emerged years after the initial implant surgery, once the implant surgical sites were fully healed, and it was only when women with BIA-ALCL noticed a change in the look or feel of their implants that the cancer diagnosis was made. As more women in the United States and around the world become aware of the potential for their breast implants to cause cancer, there will likely be additional adverse event reports submitted to the FDA in the coming months and years, as well as a significant number of anaplastic large cell lymphoma lawsuits brought against the manufacturers of breast implants.